Strategy and business model

Biotie aims in the long term to maximize shareholders’ value through optimization of value of its project portfolio. Partnering opportunities are evaluated relative to the development risk of the project in question, estimated power to negotiate favorable commercial terms, and financial resources available to the company.
 

• Well integrated in-house and outsourced preclinical and early clinical phase drug development activities
• Develop candidate drugs from validated idea to Proof of Concept
• License candidate drugs to international pharmaceutical companies
• Use comprehensive scientific network as source for new ideas